MPM18 Nov 2009 09:13
I hold here but not too impressed with the slide prior to RNS.... perhaps there is some dodgey news coming?...financing? ....a wee reminder of our future as written in 2008.
Outlook
The outlook for Minster remains exciting and full of promise.
A-TEMPUS trial result in the first quarter of 2009 that confirms
tonabersat as efficacious in the prevention of migraine and well
tolerated would put the compound on track for the final stages
of commercial development through out-licensing to a
pharmaceutical company with the expertise and resources
to take it through the registration process.
The prevention of migraine is a very large market with annual
sales currently in excess of $1 billion in the US alone and one
in which there is a clear requirement for a next-generation
preventive product.
Following the result of the TEMPUS trial we expect to accelerate
our development work on our other promising compound,
sabcomeline. Development in the management of schizophrenia
continues to support and enhance our expectations for a
viable role for sabcomeline as a treatment for this difficult and
serious condition.
Our low-cost business model means that we remain well-funded
and, with major newsflow imminent, we look forward to the future
with confidence.
John Russell
Chairman
Paul Sharpe